Danny Kessler’s Post

🚀 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒔 𝒊𝒏 𝑰𝑳-10 𝑻𝒉𝒆𝒓𝒂𝒑𝒆𝒖𝒕𝒊𝒄𝒔: 𝑨 𝑵𝒆𝒘 𝑬𝒓𝒂 𝒊𝒏 𝑰𝒎𝒎𝒖𝒏𝒆 𝑴𝒐𝒅𝒖𝒍𝒂𝒕𝒊𝒐𝒏 🔬 In the field of immunotherapy, recent breakthroughs with Interleukin-10 (IL-10) are reshaping our approach to treating autoimmune and inflammatory diseases. IL-10 has long been known for its dual nature—capable of both suppressing and stimulating immune responses. Two cutting-edge studies are paving the way for its therapeutic use. Let’s take a closer look 👇: 1️⃣ 𝙎𝙩𝙧𝙪𝙘𝙩𝙪𝙧𝙚-𝙗𝙖𝙨𝙚𝙙 𝙙𝙚𝙘𝙤𝙪𝙥𝙡𝙞𝙣𝙜 𝙤𝙛 𝙩𝙝𝙚 𝙥𝙧𝙤- 𝙖𝙣𝙙 𝙖𝙣𝙩𝙞-𝙞𝙣𝙛𝙡𝙖𝙢𝙢𝙖𝙩𝙤𝙧𝙮 𝙛𝙪𝙣𝙘𝙩𝙞𝙤𝙣𝙨 𝙤𝙛 𝙞𝙣𝙩𝙚𝙧𝙡𝙚𝙪𝙠𝙞𝙣-10 Using Cryo-EM technology 🧬, researchers have engineered a high-affinity version of IL-10 called super-10. This allows them to visualize its interaction with receptors and develop IL-10 variants that selectively target myeloid cells for anti-inflammatory effects 🔥—without activating pro-inflammatory CD8+ T cells. These discoveries could lead to better treatments for inflammatory bowel disease (IBD) and other inflammatory conditions. 2️⃣ 𝑪𝙧𝒚𝙤-𝙀𝑴 𝒉𝙚𝒍𝙥𝒔 𝒆𝙣𝒈𝙞𝒏𝙚𝒆𝙧 𝙚𝒏𝙝𝒂𝙣𝒄𝙚𝒅 𝑰𝙇-10 This study dives deeper into the development of super-10, creating IL-10 variants with enhanced receptor binding 🧩. By refining its selective interactions, these engineered variants show promise in reducing inflammation 🌿 without triggering harmful immune responses. This innovation in cytokine-based therapies could unlock new possibilities in treating autoimmune diseases. Source:https://lnkd.in/dmgg2fCp #Biotech #Immunotherapy #IL10 #Innovation #Inflammation #Healthcare #Science

ADVANCING GLOBAL HEALTH: CLINICAL TRIALS IN THE GCC REGION The Gulf Cooperation Council (GCC) region is rapidly becoming a hub for clinical trials, offering strategic advantages such as its location, advanced healthcare infrastructure, and supportive regulatory environment. With growing investments in medical research and innovation, governments in the GCC are prioritizing healthcare as part of their national visions, creating fertile ground for research and development (R&D). The region’s diverse population and high prevalence of lifestyle-related diseases like diabetes and cardiovascular conditions make it an ideal setting for trials targeting these issues. Key Focus Areas for Clinical Trials in the GCC - Chronic Diseases: Addressing high prevalence rates of diabetes, obesity, and cardiovascular diseases. - Rare Genetic Disorders: Leveraging the region’s unique genetic diversity for precision medicine research. - Oncology: Developing targeted therapies for cancer, which is a growing concern in the region. - Innovative Therapies: Exploring advanced treatments such as gene therapy, immunotherapy, and regenerative medicine. Equipped with world-class healthcare facilities, skilled professionals, and globally accredited hospitals, the GCC ensures quality and reliability in clinical trials. Streamlined regulatory frameworks, data privacy laws, and ethical oversight further enhance its appeal for global sponsors. Significant investments in R&D, biotech, and pharmaceutical sectors, alongside partnerships with private entities and global institutions, are boosting the region’s capabilities. Additionally, the GCC’s central location as a bridge between Europe, Asia, and Africa facilitates efficient logistics and stakeholder collaboration, solidifying its position as a prime destination for clinical trials. #biotech #research #investments #healthcare #healthtech #clinicaltrial #innovation #ai

📣 Explore the latest trends shaping FemTech and women’s health this week! Read here - https://lnkd.in/gxD7vJbh Top Highlights : * Dr. Reddy's Laboratories launches toripalimab, an FDA-approved immuno-oncology drug, for treating recurrent/metastatic nasopharyngeal carcinoma in India. * India's Oncology-focused Beta Drugs raised ₹117 crore from HealthQuadFund II, Singapore-based investors, and private wealth firms for minority stake. * New York's Roon, replacing "Dr. Google," secured $15M Series A funding, valuing it $65M. Led by FirstMark, Forerunner. * Pediatric care platform Zarminali Health raised $40M seed funding by General Catalyst, launching its first locations this year. * Doron Therapeutics raised $11M Series A led by SGI. Funds will advance MOTYS™ into Phase 3 clinical studies. * Germany-based SRTD Biotech raised undisclosed seed funding led by High-Tech Gründerfonds, joined by angel investors. * Greifswald’s neoplas med GmbH secured $18M funding for innovative medical technology advancements. * Johnson & Johnson India launches "India Detects to Defeat," emphasizing early detection's role in improving lung cancer outcomes. Stay informed with our latest insights! Subscribe to our newsletter to receive the latest news and trends directly in your inbox. 📬✨ #femtech #india #womenshealth #weekly #newsletter #femtechfriday

📣 Explore the latest trends shaping FemTech and women’s health this week! Read here - https://lnkd.in/gxD7vJbh Top Highlights : * Dr. Reddy's Laboratories launches toripalimab, an FDA-approved immuno-oncology drug, for treating recurrent/metastatic nasopharyngeal carcinoma in India. * India's Oncology-focused Beta Drugs raised ₹117 crore from HealthQuadFund II, Singapore-based investors, and private wealth firms for minority stake. * New York's Roon, replacing "Dr. Google," secured $15M Series A funding, valuing it $65M. Led by FirstMark, Forerunner. * Pediatric care platform Zarminali Health raised $40M seed funding by General Catalyst, launching its first locations this year. * Doron Therapeutics raised $11M Series A led by SGI. Funds will advance MOTYS™ into Phase 3 clinical studies. * Germany-based SRTD Biotech raised undisclosed seed funding led by High-Tech Gründerfonds, joined by angel investors. * Greifswald’s neoplas med GmbH secured $18M funding for innovative medical technology advancements. * Johnson & Johnson India launches "India Detects to Defeat," emphasizing early detection's role in improving lung cancer outcomes. Stay informed with our latest insights! Subscribe to our newsletter to receive the latest news and trends directly in your inbox. 📬✨ hashtag #femtech hashtag #india hashtag #womenshealth hashtag #weekly hashtag #newsletter hashtag #femtechfriday …more

Woke up to a fascinating article about biotechs developing novel therapies to support growing demand for obesity medications that promote healthy aging by helping people lose weight and maintain healthier body compositions. I know we can all relate! Thanks very much to Brian Gormley at The Wall Street Journal for taking the time to speak to me and write about Juvena’s efforts at developing a pipeline of biologics that enhance tissue regeneration, reduce inflammation, and promote metabolism to ultimately restore and repair tissues like muscle, bone and fat to treat both chronic and rare diseases including obesity and muscular dystrophies. As we continue to unlock the therapeutic potential of stem cell-secreted proteins, we’re incredibly excited about the potential to bring to patients treatments that promote tissue restoration, metabolism, and function - and ultimately fill unmet medical needs in a uniquely holistic and regenerative way. Here’s an excerpt about Juvens from the article: “Juvena Therapeutics, similarly, is advancing its lead drug for a rare disease that causes muscle wasting, called myotonic dystrophy Type 1. The company also expects that this or a similar compound emerging from its discovery platform could be combined with an incretin to preserve muscle, said CEO Hanadie Yousef. Juvena, which raised $41 million in Series A financing in 2022, also has an earlier-stage compound that could work on its own or with an incretin to improve fat metabolism, she said.” Read the full story here: https://lnkd.in/gk_sZpRT

The Panel Discussion on 'Innovative Financing for Targeted Oncology Drugs to Maximise Opportunities for Patients in India' at #ETHealthLeaders brings together industry leaders and experts to explore financial models that enhance access to life-saving oncology treatments.  Dr. Rahul Bhargava, Director & Head Department of Hematology, Fortis Healthcare "We need to shift towards value-based healthcare and establish India-centric guidelines for better patient care." Jyotsna Govil, Chairperson, Indian Cancer Society - Delhi "People should prioritize regular checkups to avoid reaching a point where targeted therapy becomes necessary." Dr. Ranjit Sahoo, Additional Professor, Medical Oncology, AIIMS (All India Institute of Medical Sciences, New Delhi) "Expensive drugs need to be used more economically and innovatively on India patients" Gopal Agrawal, Head of Pricing & Market Access, Takeda India "We need to leverage health economics data in India" Jose Peter, Co-Founder and CEO, Arogya Finance "Access to a cure is important but access to finance is even more important" Dr. Indira Behara Tankha, Vice President, Global Health Strategies (Moderator) Know More: https://bit.ly/3xKJwWC #ETHealthWorld #HealthcareFuture #Summit #EconomicTimes #IndustryLeaders #Innovation #HealthcareLeadership

📣 Explore the latest trends shaping FemTech and women’s health this week! Read here - https://lnkd.in/gxD7vJbh Top Highlights : * Dr. Reddy's Laboratories launches toripalimab, an FDA-approved immuno-oncology drug, for treating recurrent/metastatic nasopharyngeal carcinoma in India. * India's Oncology-focused Beta Drugs raised ₹117 crore from HealthQuadFund II, Singapore-based investors, and private wealth firms for minority stake. * New York's Roon, replacing "Dr. Google," secured $15M Series A funding, valuing it $65M. Led by FirstMark, Forerunner. * Pediatric care platform Zarminali Health raised $40M seed funding by General Catalyst, launching its first locations this year. * Doron Therapeutics raised $11M Series A led by SGI. Funds will advance MOTYS™ into Phase 3 clinical studies. * Germany-based SRTD Biotech raised undisclosed seed funding led by High-Tech Gründerfonds, joined by angel investors. * Greifswald’s neoplas med GmbH secured $18M funding for innovative medical technology advancements. * Johnson & Johnson India launches "India Detects to Defeat," emphasizing early detection's role in improving lung cancer outcomes. Stay informed with our latest insights! Subscribe to our newsletter to receive the latest news and trends directly in your inbox. 📬✨ hashtag #femtech hashtag #india hashtag #womenshealth hashtag #weekly hashtag #newsletter hashtag #femtechfriday …more

🚨The Frontier of CAR-T Therapies in #AutoimmuneDiseases: Navigating Risks and Opportunities🚨 🌍 The world of CAR-T therapies is evolving, with promising potential in treating autoimmune diseases like lupus nephritis. Yet, as with any groundbreaking innovation, challenges arise that demand our attention. Recently, Cabaletta Bio's candidate, CABA-201, faced a significant hurdle when a patient experienced a grade 4 neurotoxicity event. This incident has raised concerns across the industry, highlighting the delicate balance between innovation and patient safety. ⚠️ While high-grade #ICANS (immune effector cell-associated neurotoxicity syndrome) is a known risk in CAR-T therapies, this marks the first occurrence in autoimmune clinical trials. The patient, who had severe, refractory lupus, fortunately recovered after standard management, but the event serves as a critical reminder of the complexities involved in treating autoimmune patients with CAR-T therapies. 🧩 As we push the boundaries of what’s possible, it’s essential to ask ourselves: How do we navigate these risks while still advancing potentially life-saving treatments? The path forward will undoubtedly involve refining patient selection, enhancing monitoring protocols, and broadening our understanding of how these powerful therapies interact with complex autoimmune conditions. 🔍 What are your thoughts? How can the biotech industry better balance innovation with patient safety in the development of CAR-T therapies? Share your insights below! --- 👋 Hi, I’m Nia! I’m passionate about exploring the latest advancements in immunology, therapeutics, biotech, and startups. If you’re as fascinated by the future of healthcare as I am, hit that follow button for more insights, discussions, and cutting-edge news. Let’s stay connected and keep the conversation going! #Biotech #CART #PatientSafety #Innovation #Healthcare #Immunology #Startups

Great news: 👏Our Deep Tech portfolio company eleva recently shared promising preclinical data in the 'Frontiers in Immunology' journal. eleva developed a special treatment called CPV-104 to help people with complement-related issues. CPV-104 targets problems in the body's complement system, which can cause diseases like 🔸C3 Glomerulopathy (C3G), 🔸aHUS, 🔸and dry AMD. The advantage of CPV-104 is that it fixes these issues without compromising the body's ability to fight infections. Tests with CPV-104 showed that can restore kidney health and reduce harmful deposits. eleva plans to conduct clinical trials at the beginning of 2025. Andreas Schaaf, Chief Scientific Officer at eleva, stated: “CPV-104 has the potential to provide a therapeutic option that is clearly differentiated from the standard-of-care by leaving the immune system’s ability to fight infections intact.” We are hopeful for for further positive results and are delighted to have a company in our portfolio that is committed to people's health. You can find more about eleva on their website linked in our comments ⤵️. We will also link the research article. Have fun reading☺️🔖. #startups #vc #eleva #management #entrepreneurship #innovation